BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

  October 13, 2025

   · 

  2 min read
• Press Releases

  Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

  October 13, 2025

   · 

  12 min read
• Press Releases

  AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

  October 13, 2025

   · 

  13 min read
• Press Releases

  Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

  October 13, 2025

   · 

  28 min read
• Press Releases

  Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO

  October 13, 2025

   · 

  15 min read
• Press Releases

  AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

  October 13, 2025

   · 

  19 min read
• Press Releases

  United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

  October 13, 2025

   · 

  4 min read
• 

  Layoffs

  Novo Retreats From Cell Therapy, Axes Hundreds as Restructuring Rolls On

  Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to reveal which offices and locations will be affected.

  October 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Moderna Claims Early Victory for Cancer Antigen in Melanoma

  Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with efficacy increasing to 67% in those positive for PD-L1.

  October 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Chaos at CDC Continues as Hundreds Fired, Rehired

  The last few months have been tumultuous for the CDC, which has seen the ouster of Director Susan Monarez and all 17 members of the Advisory Committee on Immunization Practices.

  October 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac